|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
US5510357A
(en)
|
1995-02-28 |
1996-04-23 |
Eli Lilly And Company |
Benzothiophene compounds as anti-estrogenic agents
|
|
NZ333903A
(en)
|
1996-07-24 |
2000-02-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
|
|
US5916916A
(en)
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
|
ZA982877B
(en)
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
|
CA2287387C
(en)
|
1997-05-14 |
2010-02-16 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for destruction of selected proteins
|
|
JP2001517664A
(ja)
|
1997-09-23 |
2001-10-09 |
イーライ・リリー・アンド・カンパニー |
ベンゾチオフェン類
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
US6333344B1
(en)
|
1999-05-05 |
2001-12-25 |
Merck & Co. |
Prolines as antimicrobial agents
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
CA2432932A1
(en)
|
2001-02-16 |
2002-08-29 |
Mark A. Scialdone |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
WO2004005248A1
(en)
|
2002-07-02 |
2004-01-15 |
Novartis Ag |
Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
|
|
US7915293B2
(en)
|
2003-05-30 |
2011-03-29 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
|
US7932382B2
(en)
|
2004-01-16 |
2011-04-26 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
WO2005094818A1
(en)
|
2004-03-23 |
2005-10-13 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of iap
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
BRPI0511350A
(pt)
|
2004-07-02 |
2007-12-04 |
Genentech Inc |
composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
ES2456671T3
(es)
|
2005-02-25 |
2014-04-23 |
Tetralogic Pharmaceuticals Corporation |
Inhibidores diméricos de IAP
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
|
|
WO2006113942A2
(en)
|
2005-04-20 |
2006-10-26 |
Schering Corporation |
Method of inhibiting cathepsin activity
|
|
KR20080042158A
(ko)
|
2005-08-31 |
2008-05-14 |
셀진 코포레이션 |
이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
|
|
BRPI0708524A2
(pt)
|
2006-03-03 |
2011-05-31 |
Novartis Ag |
compostos de n-formil hidroxilamina
|
|
WO2007101347A1
(en)
|
2006-03-07 |
2007-09-13 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
US20070218138A1
(en)
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
|
JP5230610B2
(ja)
|
2006-05-05 |
2013-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
二価ｓｍａｃ模倣物およびその使用
|
|
JP2009544620A
(ja)
|
2006-07-20 |
2009-12-17 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト
|
|
US20100056495A1
(en)
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
MX2009001989A
(es)
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
|
RU2448101C2
(ru)
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
WO2008109057A1
(en)
|
2007-03-02 |
2008-09-12 |
Dana-Farber Cancer Institute, Inc. |
Organic compounds and their uses
|
|
JP5454943B2
(ja)
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク． |
抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
|
|
WO2008128171A2
(en)
|
2007-04-13 |
2008-10-23 |
The Regents Of The University Of Michigan |
Diazo bicyclic smac mimetics and the uses thereof
|
|
PE20130150A1
(es)
|
2007-04-30 |
2013-02-27 |
Genentech Inc |
Inhibidores de las iap
|
|
WO2008144925A1
(en)
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
|
JP5451602B2
(ja)
|
2007-06-08 |
2014-03-26 |
アッヴィ・インコーポレイテッド |
キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類
|
|
KR20100038108A
(ko)
|
2007-07-25 |
2010-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
트리아진 키나제 억제제
|
|
ES2534899T3
(es)
*
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
|
EP2058312A1
(en)
|
2007-11-09 |
2009-05-13 |
Universita' degli Studi di Milano |
SMAC mimetic compounds as apoptosis inducers
|
|
PE20110547A1
(es)
|
2008-10-29 |
2011-08-04 |
Celgene Corp |
Compuestos de isoindolina con actividad anticancerigena
|
|
JP5487214B2
(ja)
|
2008-12-19 |
2014-05-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
|
|
US20120135089A1
(en)
|
2009-03-17 |
2012-05-31 |
Stockwell Brent R |
E3 ligase inhibitors
|
|
WO2010141805A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of trpa1
|
|
JP2012532929A
(ja)
|
2009-07-13 |
2012-12-20 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二機能性のステープリングされたポリペプチドおよびそれらの使用
|
|
EP2784076A1
(en)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Dimeric SMAC mimetics
|
|
US8440693B2
(en)
*
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
EP2536706B1
(en)
|
2010-02-11 |
2017-06-14 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
SG186389A1
(en)
|
2010-06-30 |
2013-01-30 |
Univ Brandeis |
Small-molecule-targeted protein degradation
|
|
EP2619184B1
(en)
|
2010-09-24 |
2018-05-23 |
The Regents of the University of Michigan |
Deubiquitinase inhibitors and methods for use of the same
|
|
CN102477033A
(zh)
|
2010-11-23 |
2012-05-30 |
苏州波锐生物医药科技有限公司 |
苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
|
|
AU2011338615B2
(en)
|
2010-12-07 |
2017-07-27 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
US20140243282A1
(en)
|
2010-12-31 |
2014-08-28 |
Satish Reddy Kallam |
Methods and compositions for designing novel conjugate therapeutics
|
|
US8889684B2
(en)
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
MX352672B
(es)
|
2011-09-27 |
2017-12-04 |
Amgen Inc |
Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
|
|
WO2013071035A1
(en)
|
2011-11-09 |
2013-05-16 |
Ensemble Therapeutics |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
|
WO2013071039A1
(en)
|
2011-11-09 |
2013-05-16 |
Ensemble Therapeutics |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
|
CN103159736B
(zh)
|
2011-12-10 |
2015-05-13 |
通化济达医药有限公司 |
取代的吡唑激酶抑制剂
|
|
US9273046B2
(en)
|
2011-12-31 |
2016-03-01 |
Beigene, Ltd. |
Fused tricyclic compounds as Raf kinase inhibitors
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
US20150119435A1
(en)
|
2012-05-11 |
2015-04-30 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
|
NZ631477A
(en)
|
2012-05-30 |
2016-12-23 |
Hoffmann La Roche |
Substituted pyrrolidine-2-carboxamides
|
|
US9345740B2
(en)
|
2012-07-10 |
2016-05-24 |
Bristol-Myers Squibb Company |
IAP antagonists
|
|
US9371568B2
(en)
|
2012-07-31 |
2016-06-21 |
Novartis Ag |
Markers associated with human double minute 2 inhibitors
|
|
DK2882737T3
(da)
*
|
2012-08-09 |
2019-05-13 |
Celgene Corp |
Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
|
|
WO2014025759A1
(en)
|
2012-08-09 |
2014-02-13 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
TWI586668B
(zh)
|
2012-09-06 |
2017-06-11 |
第一三共股份有限公司 |
二螺吡咯啶衍生物之結晶
|
|
WO2014047024A1
(en)
|
2012-09-18 |
2014-03-27 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
US9603889B2
(en)
|
2012-10-02 |
2017-03-28 |
Bristol-Myers Squibb Company |
IAP antagonists
|
|
TW201428002A
(zh)
|
2012-11-09 |
2014-07-16 |
必治妥美雅史谷比公司 |
用於抑制細胞凋亡抑制劑之巨環化合物
|
|
US9637493B2
(en)
|
2012-12-20 |
2017-05-02 |
Merck Sharp & Dohme Corp. |
Substituted pyrrolopyrimidines as HDM2 inhibitors
|
|
TW201429969A
(zh)
|
2012-12-20 |
2014-08-01 |
Merck Sharp & Dohme |
作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
|
CA2902856C
(en)
|
2013-02-28 |
2021-02-16 |
Amgen Inc. |
A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
|
|
AU2014236812B2
(en)
|
2013-03-14 |
2018-03-01 |
Amgen Inc. |
Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3019517A1
(en)
|
2013-07-12 |
2016-05-18 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
ES2883289T3
(es)
*
|
2013-12-20 |
2021-12-07 |
Astex Therapeutics Ltd |
Compuestos heterocíclicos bicíclicos y sus usos en terapia
|
|
JP2017507964A
(ja)
|
2014-03-13 |
2017-03-23 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エストロゲン受容体モジュレーターを用いた治療的組合せ
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
CN107406424B
(zh)
|
2014-12-18 |
2020-08-25 |
豪夫迈·罗氏有限公司 |
雌激素受体调节剂及其用途
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
KR20180119570A
(ko)
|
2016-03-15 |
2018-11-02 |
메리맥 파마슈티컬즈, 인크. |
항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3445357B1
(en)
|
2016-04-22 |
2021-05-26 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
BR112018075206A2
(pt)
*
|
2016-06-06 |
2019-03-19 |
Celgene Corporation |
tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
CA3042301A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
FI3835298T3
(fi)
|
2019-12-12 |
2024-07-29 |
Accutar Biotechnology Inc |
Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
|
|
CN115996918A
(zh)
|
2020-05-09 |
2023-04-21 |
阿尔维纳斯运营股份有限公司 |
制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
CN113816927B
(zh)
|
2021-11-23 |
2022-02-25 |
苏州国匡医药科技有限公司 |
一种arv-471中间体的制备方法
|